Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review

IF 3.4 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Drug Safety Pub Date : 2024-04-25 DOI:10.1177/20420986231224214

Federica Martorana, Maria Vita Sanò, Maria Rosaria Valerio, Stefano Fogli, Paolo Vigneri, Romano Danesi, Vittorio Gebbia

{"title":"Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review","authors":"Federica Martorana, Maria Vita Sanò, Maria Rosaria Valerio, Stefano Fogli, Paolo Vigneri, Romano Danesi, Vittorio Gebbia","doi":"10.1177/20420986231224214","DOIUrl":null,"url":null,"abstract":"Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2− breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic, pharmacokinetic, and of its drug–drug interactions (DDIs) is crucial for an optimal patients management. Additionally, ABE interference with food and complementary/alternative medicines should be taken into account in the clinical practice. Several online tools allow to freely check DDIs and can be easily consulted before prescribing ABE. According to one of this instruments, ABE display the lowest number of interactions among the available cyclin-dependent kinase 4/6 inhibitors. Still, clinicians should be aware that online tools cannot replace the technical datasheet of the drug as well as a comprehensive clinical assessment for each patient. Here we critically review the main pharmacological features of ABE, then focusing on its potential interactions with drugs, food, and alternative medicine, in order to provide a guide for its optimal use in the treatment of HR+/HER2− breast cancer patients.","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986231224214","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2− breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic, pharmacokinetic, and of its drug–drug interactions (DDIs) is crucial for an optimal patients management. Additionally, ABE interference with food and complementary/alternative medicines should be taken into account in the clinical practice. Several online tools allow to freely check DDIs and can be easily consulted before prescribing ABE. According to one of this instruments, ABE display the lowest number of interactions among the available cyclin-dependent kinase 4/6 inhibitors. Still, clinicians should be aware that online tools cannot replace the technical datasheet of the drug as well as a comprehensive clinical assessment for each patient. Here we critically review the main pharmacological features of ABE, then focusing on its potential interactions with drugs, food, and alternative medicine, in order to provide a guide for its optimal use in the treatment of HR+/HER2− breast cancer patients.

查看原文本刊更多论文

阿柏西尼治疗HR+/HER2-乳腺癌的药理学和相互作用：重要综述

Abemaciclib（ABE）联合内分泌治疗是内分泌耐药转移性乳腺癌或高危早期HR+/HER2-乳腺癌患者的主要治疗方法。因此，充分了解这种药物的药效学、药代动力学及其药物间相互作用（DDIs）对于优化患者管理至关重要。此外，在临床实践中还应考虑到 ABE 与食物和补充/替代药物的相互作用。有几种在线工具可以免费检查 DDIs，在开具 ABE 处方之前可以很容易地进行查询。其中一种工具显示，在现有的细胞周期蛋白依赖性激酶 4/6 抑制剂中，ABE 的相互作用最少。尽管如此，临床医生仍应认识到，在线工具无法取代药物的技术数据表以及针对每位患者的全面临床评估。在此，我们认真回顾了 ABE 的主要药理特征，然后重点介绍了其与药物、食物和替代药物的潜在相互作用，以便为在治疗 HR+/HER2- 乳腺癌患者时最佳使用 ABE 提供指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

9 weeks

期刊介绍： Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.

文献相关原料

公司名称	产品信息	采购帮参考价格